Viking Therapeutics (VKTX) Equity Average (2016 - 2025)
Historic Equity Average for Viking Therapeutics (VKTX) over the last 11 years, with Q4 2025 value amounting to $676.0 million.
- Viking Therapeutics' Equity Average fell 2453.69% to $676.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $676.0 million, marking a year-over-year decrease of 2453.69%. This contributed to the annual value of $759.7 million for FY2025, which is 2365.46% up from last year.
- According to the latest figures from Q4 2025, Viking Therapeutics' Equity Average is $676.0 million, which was down 2453.69% from $754.2 million recorded in Q3 2025.
- Viking Therapeutics' 5-year Equity Average high stood at $927.4 million for Q2 2024, and its period low was $139.7 million during Q1 2023.
- Its 5-year average for Equity Average is $460.1 million, with a median of $309.2 million in 2023.
- In the last 5 years, Viking Therapeutics' Equity Average tumbled by 2852.93% in 2022 and then soared by 35897.3% in 2024.
- Quarter analysis of 5 years shows Viking Therapeutics' Equity Average stood at $207.5 million in 2021, then decreased by 28.53% to $148.3 million in 2022, then skyrocketed by 141.62% to $358.3 million in 2023, then skyrocketed by 150.01% to $895.9 million in 2024, then decreased by 24.54% to $676.0 million in 2025.
- Its Equity Average stands at $676.0 million for Q4 2025, versus $754.2 million for Q3 2025 and $821.2 million for Q2 2025.